查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1847612

抗減肥藥市場（按治療類型、藥物類型、給藥途徑、劑型和分銷管道分類）－全球預測 2025-2032

Anti-Obesity Therapeutics Market by Treatment Type, Drug Type, Route Of Administration, Drug Formulation, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗減肥藥市場將成長至 212.1 億美元，複合年成長率為 8.81%。

主要市場統計數據
基準年2024年 107.9億美元
預計2025年 116.9億美元
預測年份：2032年 212.1億美元
複合年成長率（%） 8.81%

對不斷發展的抗減肥藥生態系統的權威定位，強調科學進步、臨床實踐和決策者的商業性需求

全球對抗肥胖的努力正在加速發展，成為一個高風險、多學科的領域，生物醫學創新、臨床實踐、支付方決策和患者期望交織在一起。近年來，新型藥物療法不斷湧現，外科和內視鏡介入手段不斷發展，人們越來越關注長期療效和安全性。在此背景下，相關人員必須應對複雜的法規環境、不斷變化的報銷訊號以及社會對可及性和公平性日益成長的擔憂。

本執行摘要概述了塑造當今抗減肥藥格局的最重要的發展。它旨在為企業高管、臨床領導者、政策顧問、投資者以及其他需要簡潔、循證指導，以應對未來商業機會和挑戰的人士提供幫助。以下章節摘要變革性的科學變革，評估2025年美國實施的新關稅政策的影響，建構精細的市場區隔洞察，提取區域動態，分析競爭定位，並提案在保障商業性價值的同時加速病患可及性的具體行動建議。這些洞察旨在幫助企業做出明智的決策，在創新、安全和永續的市場執行之間取得平衡。

科學突破、交付創新和護理路徑調整的清晰整合，重塑治療潛力和商業策略

隨著科學、監管和商業性力量的融合，抗減肥藥領域正從漸進式改善轉向變革性變革。胜肽和腸促胰島素生物學領域的突破性進展正在重新定義治療目標和臨床預期，推動對藥物和器械干預措施的新投資。同時，真實世界證據和長期臨床計畫正在增強安全訊號和健康經濟考量，推動製造商和付款方就對患者和系統至關重要的結果進行更早的協調。

同時，給藥方式的創新和給藥通路策略改變了患者依從性的範式，並開闢了新的管道，催生了整合式護理途徑，將藥物、設備、數位支援和行為介入相結合，以實現永續的體重管理。因此，臨床開發項目越來越重視療效的持久性、耐受性和相對有效性，而商業化策略則強調差異化的價值提案、患者支持服務以及與專科和初級保健提供者的合作。這些轉型變革要求相關人員採用敏捷的證據產生計劃和涵蓋產品、付款人和提供者生態系統的整體上市模式。

分析近期的關稅政策如何推動抗肥胖產品整個生命週期的供應鏈彈性、採購轉變和商業性協調

2025年美國關稅為抗減肥藥供應鏈中的製造商、經銷商和醫療保健提供者帶來了新的考量。關稅政策只是眾多因素之一，它將對採購、定價策略和分銷物流直接的營運影響。受關稅影響的投入品企業必須審查供應商契約，盡可能增加國內採購，並模擬貿易流量和合約義務的下游影響。

除了採購之外，關稅也促使公司內部更積極主動地進行跨職能協調，迫使商業、監管和供應團隊合作制定緩解策略，在保護淨利率的同時維護病患的用藥管道。對於一些製造商而言，政策環境加速了其計劃，使其將某些生產活動本地化或重新配置產品包裝和分銷地點，以最大限度地降低關稅的影響。對於付款人和提供者而言，關稅強調了透明定價以及積極參與處方集配置和事先核准流程的重要性。簡言之，2025年關稅的累積影響凸顯了供應鏈彈性和策略採購是抗減肥藥商業規劃的核心要素。

基於策略細分的洞察揭示了治療、交付、配方和管道方面的差異，這些差異指導了開發重點和商業化選擇

細分洞察提供了將臨床開發與商業性執行和患者需求相結合所需的詳細觀點。根據治療類型，市場透過藥物和療法進行考察；藥物進一步探索了布丙酮-納曲酮、Liraglutide、奧利司他、芬特明-托吡酯、Semaglutide和替澤帕肽；療法透過可調節胃束帶手術、內視鏡袖狀胃成形術和胃繞道手術進行評估。這雙軸突顯了藥物創新和程序干預如何在護理路徑中共存和競爭，以及長期藥物治療與一次性或單獨的程序干預之間的決策差異。

目錄

第1章：前言

第2章調查方法

第3章執行摘要

第4章 市場概況

第5章 市場洞察

  • GLP-1受體促效劑核准用於不同族群的慢性體重管理
  • 增加針對食慾調節途徑的口服小分子候選藥物的投資
  • 擴大 GLP-1 類似物和 SGLT2 抑制劑的聯合治療可望提高療效。
  • 整合數位治療和遠端監控，支持患者堅持減重
  • 益生元和後生元配方調節腸道菌叢對肥胖症越來越重要
  • 開發口服生物有效性和安全性較高的胜肽類減重藥物
  • 不斷發展的監管途徑，以適應基於替代終點的新型肥胖症治療的加速核准
  • 針對肥胖和METABOLIC INC.易感性的個人化營養補充劑的出現
  • 製藥公司與科技Start-Ups合作開發用於肥胖治療的人工智慧決策支援工具

第6章：2025年美國關稅的累積影響

第7章：人工智慧的累積影響，2025年

第 8 章：依治療類型分類的抗減肥藥市場

  • 製藥
    • 布丙酮-納曲酮
    • Liraglutide
    • 奧利司他
    • 芬特明-托吡酯
    • Semaglutide
    • Tirzepatide
  • 治療
    • 可調式胃束帶手術
    • 內視鏡袖狀胃成形術
    • 胃繞道手術

第9章：按藥物類型分類的抗減肥藥市場

  • 非處方藥
  • 處方藥

第 10 章。按給藥途徑分類的抗減肥藥市場

  • 口服
    • 膠囊
    • 藥片
  • 腸外給藥
    • 靜脈
    • 皮下

第 11 章：抗減肥藥市場（依藥物配方）

  • 液體劑型
  • 半固態劑型
  • 固態劑型

第 12 章。抗減肥藥市場（按分銷管道）

  • 醫院/診所藥房
  • 網路藥局
  • 零售藥局

第13章 抗減肥藥市場（按地區）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第 14 章。抗減肥藥市場（按類別）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國抗減肥藥市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章競爭格局

  • 2024年市佔率分析
  • 2024年FPNV定位矩陣
  • 競爭分析
    • Alizyme PLC
    • Amgen Inc.
    • Arena Pharmaceuticals Inc.
    • Boehringer Ingelheim International GmbH
    • Bristol-Myers Squibb Company
    • Currax Pharmaceuticals LLC
    • Eisai Co. Ltd.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • FlaxoSithKline plc.
    • GlaxoSmithKline PLC
    • Johnson & Johnson Services Inc.
    • Merck & Co. Inc.
    • Nalpropion Pharmaceuticals Inc.
    • Norgine BV
    • Novartis AG
    • Novo Nordisk A/S
    • Orexigen Therapeutics Inc.
    • Pfizer Inc.
    • Rhythm Pharmaceuticals, Inc.
    • Sanofi SA
    • SHIONOGI & Co., Ltd.
    • Takeda Pharmaceutical Company Limited
    • Vivus Inc.
    • Zydus Lifesciences Limited
Product Code: MRR-EC2E133E33E6

The Anti-Obesity Therapeutics Market is projected to grow by USD 21.21 billion at a CAGR of 8.81% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.79 billion
Estimated Year [2025] USD 11.69 billion
Forecast Year [2032] USD 21.21 billion
CAGR (%) 8.81%

An authoritative orientation to the evolving anti-obesity therapeutics ecosystem that frames scientific advances, clinical practice, and commercial imperatives for decision-makers

The global effort to confront obesity has accelerated into a high-stakes, multidisciplinary arena where biomedical innovation, clinical practice, payer decisions, and patient expectations converge. Recent years have seen the emergence of novel pharmacotherapies, evolving surgical and endoscopic interventions, and an intensified focus on long-term outcomes and safety. Against this backdrop, stakeholders must navigate a complex regulatory environment, shifting reimbursement signals, and growing public attention to access and equity.

This executive summary synthesizes the most consequential developments shaping the anti-obesity therapeutics landscape today. It is written for executives, clinical leaders, policy advisors, and investors who require a concise, evidence-based orientation to the opportunities and operational challenges ahead. In the sections that follow, we summarize transformative scientific shifts, assess the implications of new tariff policies introduced in the United States in 2025, unpack granular segmentation insights, distill regional dynamics, profile competitive positioning, and propose concrete actions to accelerate patient access while protecting commercial value. Taken together, these insights aim to enable informed decisions that balance innovation, safety, and sustainable market execution.

A clear synthesis of the scientific breakthroughs, delivery innovations, and care pathway realignments that are reshaping therapeutic possibilities and commercial strategies

The landscape for anti-obesity therapeutics has shifted from incremental improvement to transformational change as a result of converging scientific, regulatory, and commercial forces. Breakthroughs in peptide and incretin biology have redefined therapeutic targets and clinical expectations, prompting renewed investment in both pharmacologic and device-based interventions. At the same time, real-world evidence and longer-duration clinical programs have elevated safety signaling and health-economic considerations, causing manufacturers and payers to align earlier on outcomes that matter to patients and systems.

Concurrently, delivery innovations and route-of-administration strategies have altered patient adherence paradigms and opened new channels for engagement. This has driven the emergence of integrated care pathways that combine medication, device, digital support, and behavioral interventions for sustained weight management. As a result, clinical development programs increasingly prioritize durability of effect, tolerability, and comparative effectiveness, while commercialization strategies emphasize differentiated value propositions, patient support services, and partnerships with specialty and primary care providers. These transformative shifts require stakeholders to adopt agile evidence-generation plans and holistic go-to-market models that span product, payer, and provider ecosystems.

An analytical account of how recent tariff policies have compelled supply chain resilience, sourcing shifts, and commercial coordination across anti-obesity product lifecycles

The tariff measures enacted in the United States in 2025 introduced new considerations for manufacturers, distributors, and providers involved in the supply chain for anti-obesity therapeutics. Although tariff policy is only one factor among many, it has immediate operational implications for sourcing, pricing strategies, and distribution logistics. Organizations exposed to tariff-affected inputs have had to reassess supplier contracts, ramp up domestic sourcing where feasible, and model the downstream effects on trade flows and contractual obligations.

Beyond procurement, the tariffs have prompted more active cross-functional coordination within companies, compelling commercial, regulatory, and supply teams to collaborate on mitigation strategies that preserve patient access while protecting margins. For some manufacturers, the policy environment accelerated plans to localize certain production activities or to reconfigure product packaging and distribution hubs to minimize tariff exposure. For payers and providers, the tariffs have emphasized the importance of transparent pricing conversations and proactive engagement on formulary placement and prior authorization processes. In short, the cumulative impact of the 2025 tariffs has been to highlight supply chain resilience and strategic sourcing as central components of commercial planning for anti-obesity therapeutics.

Strategic segmentation-driven insights that reveal therapeutic, delivery, formulation, and channel distinctions guiding development priorities and commercialization choices

Segmentation insights provide the granular perspective necessary to align clinical development with commercial execution and patient needs. Based on Treatment Type, the market is studied across Medications and Treatments, with Medications further examined across Bupropion-Naltrexone, Liraglutide, Orlistat, Phentermine-Topiramate, Semaglutide, and Tilzepatide, while Treatments are evaluated across Adjustable Gastric Banding, Endoscopic Sleeve Gastroplasty, and Gastric Bypass Surgery. This dual axis highlights how pharmaceutical innovation and procedural interventions coexist and compete within care pathways, and how decision-making differs between chronic pharmacotherapy and one-time or episodic procedural interventions.

Based on Drug Type, the market is studied across Over-The-Counter Drugs and Prescription Drugs, reflecting distinct regulatory regimes, patient self-care behaviors, and payer interactions that influence access and adherence. Based on Route Of Administration, the market is studied across Oral Administration and Parenteral Administration, with Oral Administration further examined across Capsules and Tablets, and Parenteral Administration further examined across Intravenous and Subcutaneous, underscoring how delivery mode drives clinical adoption, patient preference, and health-system readiness. Finally, based on Drug Formulation, the market is studied across Liquid Dosage Forms, Semi-Solid Dosage Forms, and Solid Dosage Forms, while distribution considerations are captured based on Distribution Channel where the market is studied across Hospitals & Clinics Pharmacies, Online Pharmacies, and Retail Pharmacies. Together, these segmentation lenses reveal where innovation clusters, where reimbursement friction is most likely to occur, and where targeted evidence generation and patient support investments can produce the greatest commercial leverage.

A nuanced regional assessment of regulatory, payer, and clinical dynamics that dictates differentiated go-to-market tactics across major global territories

Geography continues to shape regulatory pathways, payer behavior, clinical practice norms, and patient access in ways that materially influence product strategy. In the Americas, policy debates around coverage and affordability intersect with growing clinician familiarity with novel agents, creating both access opportunities and pressure for robust outcomes data. Manufacturers operating in this region must balance aggressive evidence-generation with proactive payer engagement and patient support capabilities to ensure sustained uptake.

In Europe, Middle East & Africa, heterogeneity across national systems requires differentiated market entry and pricing strategies, with some jurisdictions prioritizing cost-effectiveness evidence and others focusing on therapeutic value in specific patient cohorts. This region often demands more localized health-economic models and targeted post-launch real-world studies. In Asia-Pacific, rapid adoption of new therapies in select urban centers is counterbalanced by variable reimbursement frameworks and supply chain complexity; the region therefore rewards flexible distribution models and partnerships with established regional healthcare providers. Across all regions, cross-border collaboration on regulatory science and harmonized approaches to safety monitoring can accelerate appropriate access while protecting patient welfare.

A comprehensive competitive synthesis revealing how pharmaceutical, biotechnology, and device firms differentiate through evidence, partnerships, and integrated care solutions

Competitive dynamics in anti-obesity therapeutics reflect a mix of large diversified pharmaceutical firms, specialized biotechs, and device-focused companies, each pursuing strategies that combine clinical differentiation with scalable commercialization. Established biopharmaceutical companies leverage development expertise and global distribution networks to pursue broad indications and lifecycle management, while biotechs frequently focus on novel mechanisms of action, targeted patient segments, and partnership-driven commercialization.

Device and procedural players emphasize outcomes that matter in surgical and endoscopic interventions, investing in training, center-of-excellence models, and integration with ambulatory care pathways. Across all company types, strategic priorities include demonstrating comparative effectiveness versus existing standards, developing patient support ecosystems that improve adherence and persistence, and building payer evidence that links clinical outcomes to economic benefit. As competition intensifies, alliances between drug and device innovators, digital health providers, and specialty care networks are likely to increase, reflecting a marketplace where integrated solutions that span prevention, treatment, and long-term management create durable competitive advantages.

Practical and prioritized actions for executives to align evidence generation, patient support, supply resilience, and partnerships for durable commercial success

To convert scientific promise into sustainable impact, industry leaders should prioritize several actionable moves. First, align clinical development with payer evidence needs by embedding health-economic endpoints and pragmatic outcomes into pivotal and post-marketing studies; this will shorten time-to-coverage discussions and reduce access friction. Second, invest in patient-centric support models that address initiation, adherence, and tolerability management, recognizing that real-world persistence is a critical driver of long-term therapeutic value.

Third, strengthen supply chain resilience through diversified sourcing and regional manufacturing where appropriate, thereby mitigating tariff exposure and ensuring consistent product availability. Fourth, pursue partnerships that integrate pharmacologic treatments with device-based interventions, digital therapeutics, and behavioral programs to create differentiated value propositions for clinicians and payers. Finally, engage proactively with regulators and payers to design adaptive evidence-generation pathways that can incorporate real-world data and conditional coverage arrangements. By operationalizing these recommendations, organizations can accelerate responsible access while safeguarding commercial viability.

A transparent mixed-methods research approach combining stakeholder interviews, clinical literature review, regulatory analysis, and scenario-based synthesis to underpin conclusions

This research draws on a mixed-methods approach that integrates primary and secondary sources to deliver a rigorous, multi-dimensional perspective. Primary research includes structured interviews with stakeholders across clinical, payer, industry, and distribution channels, supplemented by detailed reviews of regulatory guidance and publicly available clinical trial registries. Secondary analysis encompassed peer-reviewed clinical literature, safety updates, and published health-technology assessment decisions to ensure the evidence base reflects both efficacy and real-world performance.

Analytical methods combined thematic synthesis with scenario analysis to explore strategic sensitivities such as reimbursement shifts, supply chain interruptions, and evolving standard-of-care practices. Where appropriate, triangulation across data sources was used to validate findings and highlight areas of consensus or divergence among stakeholders. The methodology emphasizes transparency in source attribution and methodological choices so that readers can assess the applicability of insights to their specific operating contexts.

A concise synthesis of strategic imperatives emphasizing evidence, patient access, and integrated care models as decisive factors for long-term impact

In conclusion, the anti-obesity therapeutics landscape is entering a maturation phase defined by meaningful scientific progress, heightened expectations for safety and long-term outcomes, and complex commercial dynamics that include supply chain and policy considerations. Success in this environment will depend on the ability of organizations to generate compelling comparative evidence, deploy patient-centric support programs, and adapt operational models to mitigate tariff and sourcing risks. At the same time, opportunities abound for those who can integrate pharmacologic innovation with procedural options and digital supports to deliver comprehensive, sustainable care pathways.

Going forward, stakeholders who combine rigorous clinical development, agile commercial execution, and proactive payer engagement will be best positioned to translate breakthroughs into widespread, equitable patient access. The strategic choices made now-about evidence strategy, partnerships, and organizational capabilities-will determine which therapies achieve lasting clinical and commercial impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Surge in GLP-1 receptor agonist approvals for chronic weight management in diverse populations
  • 5.2. Rising investment in oral small molecule candidates targeting appetite regulatory pathways
  • 5.3. Expansion of combination therapies pairing GLP-1 analogs with SGLT2 inhibitors for enhanced efficacy
  • 5.4. Integration of digital therapeutics and remote monitoring to support patient weight loss adherence
  • 5.5. Growing emphasis on gut microbiome modulation through prebiotic and postbiotic formulations in obesity
  • 5.6. Development of peptide-based weight loss drugs with improved oral bioavailability and safety profiles
  • 5.7. Regulatory pathways evolving to accommodate accelerated approval of novel obesity therapies based on surrogate endpoints
  • 5.8. Emergence of personalized nutraceuticals targeting genetic predispositions to obesity and metabolic syndrome
  • 5.9. Collaboration between pharmaceutical and tech startups to develop AI driven obesity treatment decision support tools

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anti-Obesity Therapeutics Market, by Treatment Type

  • 8.1. Medications
    • 8.1.1. Bupropion-Naltrexone
    • 8.1.2. Liraglutide
    • 8.1.3. Orlistat
    • 8.1.4. Phentermine-Topiramate
    • 8.1.5. Semaglutide
    • 8.1.6. Tilzepatide
  • 8.2. Treatments
    • 8.2.1. Adjustable Gastric Banding
    • 8.2.2. Endoscopic Sleeve Gastroplasty
    • 8.2.3. Gastric Bypass Surgery

9. Anti-Obesity Therapeutics Market, by Drug Type

  • 9.1. Over-The-Counter Drugs
  • 9.2. Prescription Drugs

10. Anti-Obesity Therapeutics Market, by Route Of Administration

  • 10.1. Oral Administration
    • 10.1.1. Capsules
    • 10.1.2. Tablets
  • 10.2. Parenteral Administration
    • 10.2.1. Intravenous
    • 10.2.2. Subcutaneous

11. Anti-Obesity Therapeutics Market, by Drug Formulation

  • 11.1. Liquid Dosage Forms
  • 11.2. Semi-Solid Dosage Forms
  • 11.3. Solid Dosage Forms

12. Anti-Obesity Therapeutics Market, by Distribution Channel

  • 12.1. Hospitals & Clinics Pharmacies
  • 12.2. Online Pharmacies
  • 12.3. Retail Pharmacies

13. Anti-Obesity Therapeutics Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Anti-Obesity Therapeutics Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Anti-Obesity Therapeutics Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Alizyme PLC
    • 16.3.2. Amgen Inc.
    • 16.3.3. Arena Pharmaceuticals Inc.
    • 16.3.4. Boehringer Ingelheim International GmbH
    • 16.3.5. Bristol-Myers Squibb Company
    • 16.3.6. Currax Pharmaceuticals LLC
    • 16.3.7. Eisai Co. Ltd.
    • 16.3.8. Eli Lilly and Company
    • 16.3.9. F. Hoffmann-La Roche Ltd
    • 16.3.10. FlaxoSithKline plc.
    • 16.3.11. GlaxoSmithKline PLC
    • 16.3.12. Johnson & Johnson Services Inc.
    • 16.3.13. Merck & Co. Inc.
    • 16.3.14. Nalpropion Pharmaceuticals Inc.
    • 16.3.15. Norgine B.V.
    • 16.3.16. Novartis AG
    • 16.3.17. Novo Nordisk A/S
    • 16.3.18. Orexigen Therapeutics Inc.
    • 16.3.19. Pfizer Inc.
    • 16.3.20. Rhythm Pharmaceuticals, Inc.
    • 16.3.21. Sanofi S.A.
    • 16.3.22. SHIONOGI & Co., Ltd.
    • 16.3.23. Takeda Pharmaceutical Company Limited
    • 16.3.24. Vivus Inc.
    • 16.3.25. Zydus Lifesciences Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. ANTI-OBESITY THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. ANTI-OBESITY THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTI-OBESITY THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY BUPROPION-NALTREXONE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIRAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORLISTAT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PHENTERMINE-TOPIRAMATE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMAGLUTIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TILZEPATIDE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ADJUSTABLE GASTRIC BANDING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ENDOSCOPIC SLEEVE GASTROPLASTY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY GASTRIC BYPASS SURGERY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY OVER-THE-COUNTER DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PRESCRIPTION DRUGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY CAPSULES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TABLETS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY LIQUID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SEMI-SOLID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SOLID DOSAGE FORMS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY HOSPITALS & CLINICS PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENTS, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY ORAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY PARENTERAL ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DRUG FORMULATION, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA ANTI-OBESITY THERAPEUTICS MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA AN